Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

23 July 2019 : Meta-Analysis  

Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis

Hongsen Chen1ACG*, Chensong Chen1BF, Junjie Fang1CF, Ren Wang1AE, Wanshui Nie1BD, Qionghui Yuan1DE

DOI: 10.12659/MSM.917774

Med Sci Monit 2019; 25:5473-5481

Abstract

BACKGROUND: The aim of this study was to systematically evaluate the effect of oral Xa inhibitors plus antiplatelet therapy in the treatment of coronary artery disease.

MATERIAL AND METHODS: All randomized controlled trials (RCTs) about antiplatelet therapy plus Xa factor inhibitors for coronary artery disease from database inception to January 2019 were searched for and collected from PubMed, Embase, and the Cochrane Library. Two reviewers extracted and analyzed the data independently. Additionally, RevMan 5.0 software was applied for meta-analysis.

RESULTS: Seven RCTs with 50 044 patients were included. The meta-analysis results showed that treatment with antiplatelet therapy plus Xa factor inhibitors in patients with coronary artery disease could significantly reduce the risk of ischemic events (P<0.00001). Besides, risk of all-cause mortality (P=0.003), myocardial infarction (P=0.02) and ischemic stroke (P<0.0001) were also significantly reduced. However, risk of massive hemorrhage after TIMI (P<0.00001), minor hemorrhage after TIMI (P<0.00001), and intracranial hemorrhage (P=0.006) were significantly increased, respectively. Xa inhibition drugs also intended to increase risk of fatal bleeding, but there was no significant difference (P=0.08).

CONCLUSIONS: Antiplatelet therapy plus Xa factor inhibitors in patients with coronary artery disease was effective, which could reduce the risk of ischemic composite endpoints, all-cause mortality, myocardial infarction, and ischemic stroke. However, it could significantly increase risk of bleeding in terms of safety.

Keywords: Coronary Disease, meta-analysis, Platelet Aggregation Inhibitors, acute coronary syndrome, Anticoagulants, Coronary Artery Disease, Factor Xa Inhibitors, Hemorrhage, Myocardial Infarction, Stroke, Treatment Outcome

0 Comments

Editorial

01 March 2023 : Editorial  

Editorial: Global Surveillance of Highly Pathogenic Avian Influenza Viruses in Poultry, Wild Birds, and Mammals to Prevent a Human Influenza Pandemic

Dinah V. Parums

DOI: 10.12659/MSM.939968

Med Sci Monit 2023; 29:e939968

SARS-CoV-2/COVID-19

In Press

24 Mar 2023 : Database Analysis  

Causes of Death Following Gastric Cancer Diagnosis: A Population-Based Analysis

Med Sci Monit In Press; DOI: 10.12659/MSM.939848  

22 Mar 2023 : Special report  

One Year On: Poland’s Public Health Initiatives and National Response to Millions of Refugees from Ukraine

Med Sci Monit In Press; DOI: 10.12659/MSM.940223  

22 Mar 2023 : Clinical Research  

Value of IL-1β and IL-23 in Predicting 28-Day Mortality Due to Sepsis: A Retrospective Study

Med Sci Monit In Press; DOI: 10.12659/MSM.940163  

21 Mar 2023 : Clinical Research  

Efficacy of Direct Anterior Approach Versus Posterior Lateral Approach for Total Hip Replacement in Patient...

Med Sci Monit In Press; DOI: 10.12659/MSM.939682  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750